Rosa L. Vincent

The paper introduces NanoPro, a nanovector therapy platform using probiotically-released tumor-binding tags to target antigenically indistinct tumors, demonstrating in vitro efficacy with high transduction rates.

This study shows engineered E. coli expressing CXCL13 enhances bladder cancer immunotherapy when combined with PD-1 blockade by promoting tumor-specific antibody responses.

This study engineers probiotic E. coli to deliver neoantigen peptides, enhancing T cell immunity and reducing tumor growth in mice.

The paper designs a probiotic platform to deliver checkpoint blockade nanobodies to tumors using a controlled lysing mechanism for therapeutic release.